While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

Methode Electronics posted adjusted loss of 77 cents per share, missing market estimates of earnings of 4 cents per share, ...

Metsera is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could ...

MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related events, with consistent findings in further analyses, according to new ...

Ireland’s premier life sciences celebration recognises industry excellence with 217 attendees witnessing record-breaking ...

CHICAGO — Mifepristone treatment improved glycemic control and led to weight loss and a reduction of waist circumference in patients with poorly controlled type 2 diabetes (T2D) and hypercortisolism, ...

Wells Fargo emphasized that Metsera’s long half-life drugs may provide improved tolerability by enabling gradual buildup of drug exposure and avoiding fluctuations that increase adverse events. The ...

The market worth was recorded at $3.16 billion in 2024 and is projected to escalate to $3.68 billion in 2025, unfolding at a robust compound annual growth rate CAGR of 16.1%. The proficient growth in ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another ...

Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and ...